THE MISSION IS TO HARNESS OUR CREATIVITY INTO A VIABLE SOLUTION

C3D Patented Solution to Make Cancer Irrelevant

Chemosen3D proprietary magnetic 3D-based platform tests anti-cancer agents ex vivo to determine reactive therapies on a per patient basis, avoiding the cost and risk to individuals of receiving ineffective drug regimens. ChemoSen3D’s functional 3D assay is poised to be part of pre-screening protocols, along with molecular testing, for personalized treatment decisions. Our approach utilizes magnetic 3D bio-printing to create patient-derived spheroid for chemo-response testing which maintains tissue heterogeneity: a critical factor for drugresponse determination in physiologically relevant models that will accelerate precision medicine profiling of cancer.

The Right Tools. The Right Solution.

ChemoSen3D’s functional 3D assay is poised to be part of pre-screening protocols, along with molecular testing, for personalized treatment decisions.

Investors

We will soon be opening our Series A Round for new investors interested in advancing our proprietary magnetic 3D technology into the oncology space.

Clinicians

Are you a clinician that sees potential for your patients?
We want to help you.

Researchers

Cell line or Primary cells that you would like to see in 3D? We can help.

ChemoSen3D grew out of Nano3D Biosciences (n3D) which was a State of Texas C-Corporation founded in 2008 by Glauco R. Souza, Thomas Killian, David Lee, and Robert Raphael. n3D commercialized products and services utilizing the Bio-Assembler™ technology created by Glauco R. Souza (U.T. MD Anderson Cancer Center), Thomas Killian (Rice University) and Robert Raphael (Rice University). The n3D business strategy has been created by all team members under the business leadership of David Lee. n3D was a Houston Technology Center client company, and it had been recognized with a Rice Alliance “Most Promising Life Science Company” award (2009), received approximately $2,000,000 in non-diluting funds from grants, a Pre-Seed Commercialization Award of $1,000,000 from the Texas Emerging Technology Fund (2010), and a $10,000 Goradia Innovation Prize (2010). N3D’s magnetic 3D culturing technology was sold to Greiner-Bio One in 2018 and now ChemoSen3D is moving forward into the clinical diagnostic space.